Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study / Larry Alphs en The Journal of Clinical Psychiatry, Año 2014 - Vol.75 - No.12 (Diciembre)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2014 - Vol.75 - No.12 (Diciembre) . - pp. 1388-1393 Título : Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study : a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia Tipo de documento: texto impreso Autores: Larry Alphs, Autor ; Lian Mao, Autor ; Stephen C. Rodriguez, Autor Fecha de publicación: 2022 Artículo en la página: pp. 1388-1393 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Hospitalización, Isoxazoles - inyección, Palmitato de paliperidona, Esquizofrenia. Resumen: Public health considerations require that clinical trials address the complex "real-world" needs of patients with chronic illnesses. This is particularly true for persons with schizophrenia, whose management is frequently complicated by factors such as comorbid substance abuse, homelessness, and contact with the criminal justice system. Link: ./index.php?lvl=notice_display&id=27852 [artículo] Design and rationale of the Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study : a novel comparative trial of once-monthly paliperidone palmitate versus daily oral antipsychotic treatment for delaying time to treatment failure in persons with schizophrenia [texto impreso] / Larry Alphs, Autor ; Lian Mao, Autor ; Stephen C. Rodriguez, Autor . - 2022 . - pp. 1388-1393. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2014 - Vol.75 - No.12 (Diciembre) . - pp. 1388-1393 Palabras clave: Antipsicóticos, Hospitalización, Isoxazoles - inyección, Palmitato de paliperidona, Esquizofrenia. Resumen: Public health considerations require that clinical trials address the complex "real-world" needs of patients with chronic illnesses. This is particularly true for persons with schizophrenia, whose management is frequently complicated by factors such as comorbid substance abuse, homelessness, and contact with the criminal justice system. Link: ./index.php?lvl=notice_display&id=27852

Onset and persistence of antipsychotic response in patients with schizophrenia / Ira D. Glick en Journal of Clinical Psychopharmacology, Año 2009 - Vol. 29 - No. 6 (Diciembre)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2009 - Vol. 29 - No. 6 (Diciembre) . - pp. 542-547 Título : Onset and persistence of antipsychotic response in patients with schizophrenia Tipo de documento: texto impreso Autores: Ira D. Glick, Autor ; Cynthia A. Bossie, Autor ; Larry Alphs, Autor Fecha de publicación: 2022 Artículo en la página: pp. 542-547 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Persistencia, Paliperidona ER, Esquizofrenia, Antipsicóticos, Respuesta Resumen: In daily practice, clinicians are interested in knowing when to expect treatment response after initiating a new antipsychotic medication. This analysis examined whether response onset and persistence can distinguish true drug from placebo responses. Link: ./index.php?lvl=notice_display&id=29477 [artículo] Onset and persistence of antipsychotic response in patients with schizophrenia [texto impreso] / Ira D. Glick, Autor ; Cynthia A. Bossie, Autor ; Larry Alphs, Autor . - 2022 . - pp. 542-547. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2009 - Vol. 29 - No. 6 (Diciembre) . - pp. 542-547 Palabras clave: Persistencia, Paliperidona ER, Esquizofrenia, Antipsicóticos, Respuesta Resumen: In daily practice, clinicians are interested in knowing when to expect treatment response after initiating a new antipsychotic medication. This analysis examined whether response onset and persistence can distinguish true drug from placebo responses. Link: ./index.php?lvl=notice_display&id=29477

Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia / Larry Alphs en The Journal of Clinical Psychiatry, Año 2015 - Vol.76 - No.5 (Mayo)

Público ISBD [artículo]  inThe Journal of Clinical Psychiatry > Año 2015 - Vol.76 - No.5 (Mayo) . - pp. 554-561 Título : Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia : a randomized, open-label, review board–blinded 15-month study Tipo de documento: texto impreso Autores: Larry Alphs, Autor ; Carmela Benson, Autor ; Kimberly Cheshire-Kinney, Autor Fecha de publicación: 2020 Artículo en la página: pp. 554-561 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Antipsicóticos, Criminales, Isoxazoles, Palmitato, Esquizofrenia. Resumen: The Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study compared the effects of once-monthly paliperidone palmitate with daily oral antipsychotics on treatment failure in adults with schizophrenia. Link: ./index.php?lvl=notice_display&id=21839 [artículo] Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia : a randomized, open-label, review board–blinded 15-month study [texto impreso] / Larry Alphs, Autor ; Carmela Benson, Autor ; Kimberly Cheshire-Kinney, Autor . - 2020 . - pp. 554-561. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The Journal of Clinical Psychiatry > Año 2015 - Vol.76 - No.5 (Mayo) . - pp. 554-561 Palabras clave: Antipsicóticos, Criminales, Isoxazoles, Palmitato, Esquizofrenia. Resumen: The Paliperidone Palmitate Research in Demonstrating Effectiveness (PRIDE) study compared the effects of once-monthly paliperidone palmitate with daily oral antipsychotics on treatment failure in adults with schizophrenia. Link: ./index.php?lvl=notice_display&id=21839

---

1 (1 - 3 / 3)